Advanced glycation end products downregulate glucokinase in mice

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 6, 2011, Pages 557-563

  Jung, Hongsoo ^a   Joo, Jindeok ^a   Jeon, Yeonsu ^a   Lee, Junga ^a   In, Janghyeok ^a   Kim, Daewoo ^a   Kang, Eujin ^a   Kim, Yongshin ^a   Lim, Yonggul ^a   Kang, Jaehyeok ^a   Choi, Jinwoo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Advanced glycation end products; Glucokinase; Glucokinase activator

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; GLUCOKINASE; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT DURATION;

ANIMALS; DOWN-REGULATION; GLUCOKINASE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; GLYCOSYLATION END PRODUCTS, ADVANCED; INSULIN; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL; SERUM ALBUMIN, BOVINE; SULFONES; THIAZOLES;

EID: 80052590678     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1208     Document Type: Article

References (35)

1. Printz RL, Magnuson MA, Granner DK. Mammalian glucokinase. Annu Rev Nutr 1993; 13: 463-496.
2. Colowick SP. The Enzymes, 1973; 9(C): 1-48. DOI: 10.1016/S1874-6047 (08)60113-4.
3. Nakamura A, Terauchi Y, Ohyama S, et al. Impact of small-molecule glucokinase activator on glucose metabolism and β-cell mass. Endocrinology 2009; 150(3): 1147-1154.
4. Matschinsky FM, Magnuson MA, Zelent D, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 2006; 55(1): 1-12.
5. Matschinsky FM, Magnuson MA (eds). Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Front Diabetes, vol 16:Karger: Basel, 2004; 31-41.
6. Hariharan N, Farrelly D, Hagan D, et al. Expression of human hepatic glucokinase in transgenic mice liver results in decreased levels and reduced body weight. Diabetes 1997; 46(1): 11-16.
7. Gloyn AL. Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum Mutat 2003; 22(5): 353-362.
8. Johnson D, Shepherd RM, Gill D, et al. Glucose-dependent modulation of insulin and intracellular calcium ions by GKA50, a glucokinase activator. Diabetes 2007; 56(6): 1694-1702.
9. Monnier V, Cerami A. Nonenzymatic browing in vivo: possible process for aging of long-lived proteins. Science 1981; 211(4481): 491-493.
10. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16(3): 271-278.
11. Goova MT, Li J, Kislinger T, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159(2): 513-525.
12. Lalla E, Lamster IB, Feit M, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000; 105(8): 1117-1124.
13. Palinski W, Koschinsky T, Butler SW, et al. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol 1995; 15(5): 571-582.
14. Santana RB, Xu L, Chase HB, et al. A role for advanced glycation end products in diminished bone healing in type 1 diabetes. Diabetes 2003; 52(6): 1502-1510.
15. Chung EY, Yoon JR. Ketamine potentiates neurotoxicity in obese mice. Korean J Anesthesiol 2008; 55: 473-478.
16. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414(6865): 813-820.
17. Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 2007; 13(27): 2832-2836.
18. Vlassara H. Advanced glycation in health and disease: role of the modern environment. Ann N Y Acad Sci 2005; 1043: 452-460.
19. Hofmann SM, Dong HJ, Li Z, et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002; 51(7): 2082-2089.
20. Sandu O, Song K, Cai W, et al. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 2005; 54(8): 2314-2319.
21. Peppa M, He C, Hattori M, et al. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 2003; 52(6): 1441-1448.
22. Ihnat MA, Thorpe JE, Ceriello A. Hypothesis: the 'metabolic memory', the new challenge of diabetes. Diabet Med 2007; 24(6): 582-586.
23. Matsuoka T, Kajimoto Y, Watada H, et al. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest 1997; 99(1): 144-150.
24. Unoki H, Yamagishi S. Advanced glycation end products and insulin resistance. Curr Pharm Design 2008; 14(10): 987-989.
25. Zhao Z, Zhao C, Zhang XH, et al. Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. Endocrinology 2009; 150(6): 2569-2576.
26. Mitsuhashi T, Vlassara H, Founds HW, et al. Standardizing the immunological measurement of advanced glycation endproducts using normal human serum. J Immunol Methods 1997; 207(1): 79-88.
27. Cai W, Gao QD, Zhu L, et al. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002; 8(7): 337-346.
28. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967; 16(1): 35-39.
29. Hofmann SM, Dong HJ, Li Z, et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002; 51(7): 2082-2089.
30. Sandu O, Song K, Cai W, et al. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 2005; 54(8): 2314-2319.
31. Niswender KD, Postic C, Jetton TL, et al. Cell-specific expression and regulation of a glucokinase gene locus transgene. J Biol Chem 1997; 272(36): 22564-22569.
32. Froguel P, Vaxillaire M, Sun F, et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 1992; 356(6365): 162-164.
33. Hattersley AT, Turner RC, Permutt MA, et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet 1992; 339(8805): 1307-1310.
34. Edghill EL, Hattersley AT. Genetic disorders of the pancreatic beta cell and diabetes (permanent neonatal diabetes and maturity-onset diabetes of the young). Pancreatic Beta Cell in Health and Disease 2008; V: 399-430.
35. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009; 8(5): 399-416. Epub 17 April 2009.